✦ LIBER ✦

PCHI4: MEDICAL TREATMENT FOR CHRONIC MYELOID LEUKAEMIA (CML):AVERAGE COST EFFECTIVENESS RATIOS OF FIRST AND SECOND LINE TREATMENT

✍ Scribed by MT Groot; GJ Ossenkoppele; MHH Kramer; G van den Boom; PC Huijgens; CA Uyl-de Groot

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Second-Generation Tyrosine Kinase Inhibi

✍ Abruzzese, Elisabetta; Breccia, Massimo; Latagliata, Roberto 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 451 KB

PCN2 COST-EFFECTIVENESS OF IMATINIB (GLE

✍ K El Ouagari; W Talbot; JF Baladi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Erratum to: Second-Generation Tyrosine K

✍ Abruzzese, Elisabetta; Breccia, Massimo; Latagliata, Roberto 📂 Article 📅 2014 🏛 Springer International Publishing AG 🌐 English ⚖ 125 KB

Cost effectiveness of imatinib compared

✍ K. Dalziel; A. Round; R. Garside; K. Stein 📂 Article 📅 2005 🏛 Springer International Publishing AG 🌐 English ⚖ 171 KB

PCN90 Cost Effectiveness Analysis of Ben

✍ S. Vandekerckhove; K. Holtzer-Goor; D. Van Den Steen; Y. van Megen; P. Huijgens; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PCN101 COST-UTILITY ANALYSIS OF DASATINI

✍ S Kuznetzov; LJ Mungapen; Y Samyshkin; DE Jakouloff; U Sbarigia; M van Baardewij 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB